Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence.
Riviere-Cazaux C, Carlstrom LP, Neth BJ, Olson IE, Rajani K, Rahman M, Ikram S, Mansour MA, Mukherjee B, Warrington AE, Short SC, von Zglinicki T, Brown DA, Burma S, Tchkonia T, Schafer MJ, Baker DJ, Kizilbash SH, Kirkland JL, Burns TC. Riviere-Cazaux C, et al. Among authors: kizilbash sh. NPJ Precis Oncol. 2023 Nov 29;7(1):126. doi: 10.1038/s41698-023-00476-8. NPJ Precis Oncol. 2023. PMID: 38030881 Free PMC article. Review.
Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas.
Riviere-Cazaux C, Carlstrom LP, Rajani K, Munoz-Casabella A, Rahman M, Gharibi-Loron A, Brown DA, Miller KJ, White JJ, Himes BT, Jusue-Torres I, Ikram S, Ransom SC, Hirte R, Oh JH, Elmquist WF, Sarkaria JN, Vaubel RA, Rodriguez M, Warrington AE, Kizilbash SH, Burns TC. Riviere-Cazaux C, et al. Among authors: kizilbash sh. Commun Biol. 2023 Jun 20;6(1):653. doi: 10.1038/s42003-023-05035-2. Commun Biol. 2023. PMID: 37340056 Free PMC article.
Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas.
Riviere-Cazaux C, Lacey JM, Carlstrom LP, Laxen WJ, Munoz-Casabella A, Hoplin MD, Ikram S, Zubair AB, Andersen KM, Warrington AE, Decker PA, Kaufmann TJ, Campian JL, Eckel-Passow JE, Kizilbash SH, Tortorelli S, Burns TC. Riviere-Cazaux C, et al. Among authors: kizilbash sh. Neurooncol Adv. 2023 May 11;5(1):vdad061. doi: 10.1093/noajnl/vdad061. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37313502 Free PMC article. No abstract available.
Survival and associated predictors for patients with pineoblastoma or pineal parenchymal tumors of intermediate differentiation older than 3 years: Insights from the National Cancer Database.
Kerezoudis P, Yolcu YU, Laack NN, Ruff MW, Khatua S, Daniels DJ, Burns TC, Kizilbash SH. Kerezoudis P, et al. Among authors: kizilbash sh. Neurooncol Adv. 2022 Apr 17;4(1):vdac057. doi: 10.1093/noajnl/vdac057. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35611271 Free PMC article.
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
Webb MJ, Neth BJ, Webb LM, Van Gompel JJ, Link MJ, Neff BA, Carlson ML, Driscoll CL, Dornhoffer J, Ruff MW, Anderson KA, Kizilbash SH, Campian JL, Uhm JH, Lane JI, Benson JC, Blezek DJ, Mehta PM, Bathla G, Sener UT. Webb MJ, et al. Among authors: kizilbash sh. Neurooncol Adv. 2023 Sep 22;5(1):vdad123. doi: 10.1093/noajnl/vdad123. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37841698 Free PMC article.
51 results